156 related articles for article (PubMed ID: 30851122)
1. Chronic long-term exposure to cadmium air pollution and breast cancer risk in the French E3N cohort.
Amadou A; Praud D; Coudon T; Danjou AMN; Faure E; Leffondré K; Le Romancer M; Severi G; Salizzoni P; Mancini FR; Fervers B
Int J Cancer; 2020 Jan; 146(2):341-351. PubMed ID: 30851122
[TBL] [Abstract][Full Text] [Related]
2. Exposure to airborne cadmium and breast cancer stage, grade and histology at diagnosis: findings from the E3N cohort study.
Amadou A; Praud D; Coudon T; Danjou AMN; Faure E; Deygas F; Grassot L; Leffondré K; Severi G; Salizzoni P; Mancini FR; Fervers B
Sci Rep; 2021 Nov; 11(1):23088. PubMed ID: 34845239
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer associated with long-term exposure to benzo[a]pyrene (BaP) air pollution: Evidence from the French E3N cohort study.
Amadou A; Praud D; Coudon T; Deygas F; Grassot L; Faure E; Couvidat F; Caudeville J; Bessagnet B; Salizzoni P; Gulliver J; Leffondré K; Severi G; Mancini FR; Fervers B
Environ Int; 2021 Apr; 149():106399. PubMed ID: 33503556
[TBL] [Abstract][Full Text] [Related]
4. Long-term airborne dioxin exposure and breast cancer risk in a case-control study nested within the French E3N prospective cohort.
Danjou AMN; Coudon T; Praud D; Lévêque E; Faure E; Salizzoni P; Le Romancer M; Severi G; Mancini FR; Leffondré K; Dossus L; Fervers B
Environ Int; 2019 Mar; 124():236-248. PubMed ID: 30658268
[TBL] [Abstract][Full Text] [Related]
5. Long-term exposure to nitrogen dioxide air pollution and breast cancer risk: A nested case-control within the French E3N cohort study.
Amadou A; Praud D; Coudon T; Deygas F; Grassot L; Dubuis M; Faure E; Couvidat F; Caudeville J; Bessagnet B; Salizzoni P; Leffondré K; Gulliver J; Severi G; Mancini FR; Fervers B
Environ Pollut; 2023 Jan; 317():120719. PubMed ID: 36435283
[TBL] [Abstract][Full Text] [Related]
6. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Bardia A; Olson JE; Vachon CM; Lazovich D; Vierkant RA; Wang AH; Limburg PJ; Anderson KE; Cerhan JR
Breast Cancer Res Treat; 2011 Feb; 126(1):149-55. PubMed ID: 20669045
[TBL] [Abstract][Full Text] [Related]
7. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
8. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.
Suzuki R; Orsini N; Saji S; Key TJ; Wolk A
Int J Cancer; 2009 Feb; 124(3):698-712. PubMed ID: 18988226
[TBL] [Abstract][Full Text] [Related]
9. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
Fagherazzi G; Chabbert-Buffet N; Fabre A; Guillas G; Boutron-Ruault MC; Mesrine S; Clavel-Chapelon F
Int J Obes (Lond); 2012 Mar; 36(3):431-9. PubMed ID: 21427693
[TBL] [Abstract][Full Text] [Related]
10. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
Dartois L; Fagherazzi G; Baglietto L; Boutron-Ruault MC; Delaloge S; Mesrine S; Clavel-Chapelon F
Int J Cancer; 2016 May; 138(10):2415-27. PubMed ID: 26756677
[TBL] [Abstract][Full Text] [Related]
11. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
[TBL] [Abstract][Full Text] [Related]
12. Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
Ge W; Clendenen TV; Afanasyeva Y; Koenig KL; Agnoli C; Brinton LA; Dorgan JF; Eliassen AH; Falk RT; Hallmans G; Hankinson SE; Hoffman-Bolton J; Key TJ; Krogh V; Nichols HB; Sandler DP; Schoemaker MJ; Sluss PM; Sund M; Swerdlow AJ; Visvanathan K; Liu M; Zeleniuch-Jacquotte A
Int J Cancer; 2018 Jun; 142(11):2215-2226. PubMed ID: 29315564
[TBL] [Abstract][Full Text] [Related]
13. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
14. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort.
Kaaks R; Tikk K; Sookthai D; Schock H; Johnson T; Tjønneland A; Olsen A; Overvad K; Clavel-Chapelon F; Dossus L; Baglietto L; Rinaldi S; Chajes V; Romieu I; Boeing H; Schütze M; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Tumino R; Ricceri F; Mattiello A; Buckland G; Ramón Quirós J; Sánchez MJ; Amiano P; Chirlaque MD; Barricarte A; Bas Bueno-de-Mesquita H; van Gils CH; Peeters PH; Andersson A; Sund M; Weiderpass E; Khaw KT; Wareham N; Key TJ; Travis RC; Merritt MA; Gunter MJ; Riboli E; Lukanova A
Int J Cancer; 2014 Apr; 134(8):1947-57. PubMed ID: 24155248
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
16. Metallic air pollutants and breast cancer heterogeneity.
Kresovich JK; Erdal S; Chen HY; Gann PH; Argos M; Rauscher GH
Environ Res; 2019 Oct; 177():108639. PubMed ID: 31419716
[TBL] [Abstract][Full Text] [Related]
17. Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women.
Anderson LN; Cotterchio M; Boucher BA; Kreiger N
Int J Cancer; 2013 Apr; 132(7):1683-92. PubMed ID: 22907507
[TBL] [Abstract][Full Text] [Related]
18. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
19. Long-term atmospheric exposure to PCB153 and breast cancer risk in a case-control study nested in the French E3N cohort from 1990 to 2011.
Deygas F; Amadou A; Coudon T; Grassot L; Couvidat F; Bessagnet B; Faure E; Salizzoni P; Gulliver J; Caudeville J; Severi G; Mancini FR; Leffondré K; Fervers B; Praud D
Environ Res; 2021 Apr; 195():110743. PubMed ID: 33450235
[TBL] [Abstract][Full Text] [Related]
20. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
